Bevacizumab may be Active in Myelofibrosis

Ilias NikolaidisOncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece, 1st Department of Medicine, Laiko General Hospital, Athens School of Medicine, Greece.

Nektaria MakriliaOncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece, 1st Department of Medicine, Laiko General Hospital, Athens School of Medicine, Greece.

Vassilia XylaOncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece, 1st Department of Medicine, Laiko General Hospital, Athens School of Medicine, Greece.

Kalliopi DilanaOncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece, 1st Department of Medicine, Laiko General Hospital, Athens School of Medicine, Greece.

Dimitris StathopoulosOncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece, 1st Department of Medicine, Laiko General Hospital, Athens School of Medicine, Greece.

Ioannis MeletisOncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece, 1st Department of Medicine, Laiko General Hospital, Athens School of Medicine, Greece.

Kostas SyrigosOncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece, 1st Department of Medicine, Laiko General Hospital, Athens School of Medicine, Greece.Correspondence[email protected] [email protected]

show all

ABSTRACT

A case of a 69-year-old woman with myelofibrosis presenting with non-small cell lung cancer was reported at Sotiria General Hospital in Athens. She was administered bevacizumab infusions biweekly and a great decrease in the number of her white blood cells was observed. Such low levels of white blood cells had never been reached in the past, when she was receiving hydroxyurea.

Keywords: :

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Bevacizumab may be Active in Myelofibrosis

Information for

Open access

Opportunities

Help and information

Bevacizumab may be Active in Myelofibrosis

ABSTRACT

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature